Dividend Kings AbbVie & Johnson & Johnson Crush Market

AbbVie and Johnson & Johnson, both Dividend Kings, have outperformed the market this year, with AbbVie soaring 29% and Johnson & Johnson close behind. AbbVies quarterly revenue surged 9.1% to $15.7 billion, driven by stars like Skyrizi and neuroscience sales. Johnson & Johnsons third-quarter sales hit $24 billion, with oncology and neuroscience drugs like Spravato surging. Both companies raised full-year guidance and dividends, offering income and growth for patient investors.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.